Over 40% of innovative medicines recommended for marketing authorisation in the European Union (EU) between 2010 and 2012 originated from small or medium-sized enterprises (SMEs), academia, public bodies and public-private partnerships, according to an article published today in Nature Reviews Drug Discovery and authored by staff members of the European Medicines Agency (EMA).
The main findings are:
- 27% of these medicines originate from SMEs, while SMEs account for only 13% of the marketing-authorisation holders;
- 17% originate from academic institutions, public bodies and public-private partnerships, while these organisations are no longer involved at the stage of marketing-authorization applications.